You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
---|---|---|---|---|---|---|
Lu AF28996 (D1-D2 agonist) | Neurology | 1 | ||||
Lu-AF41156 (D2 agonist) | Psychiatry | 2 | ||||
Lu AG06466 (MAGL inhibitor) | Psychiatry + Neurology | 1 | ||||
Lu AG09222 (anti-PACAP mAb) | Neurology | 2 |
Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
---|---|---|---|---|---|---|
Lu AF28996 (D1-D2 agonist) | Neurology | 1 | ||||
Lu-AF41156 (D2 agonist) | Psychiatry | 2 | ||||
Lu AG06466 (MAGL inhibitor) | Psychiatry + Neurology | 1 | ||||
Lu AG09222 (anti-PACAP mAb) | Neurology | 2 |
* CD40L/serum-albumin bispecific antibody-fragment ((scFv)2-Fab)) based on AprilBio’s SAFA™ technology platform.
R&D of new and improved treatments is at the core of what we do.
The journey to brain health starts with understanding the diseases in the brain.
We strive for Progress in Mind - our multifaceted approach to patients.
UK-NOTPR-1886 | April 2024